PRTCL.
Legal & Regulatory

Compounded vs brand semaglutide or tirzepatide - what's the catch?

Updated 2026-05-02

Brand medications (Wegovy, Ozempic, Mounjaro, Zepbound) are made by Novo Nordisk or Eli Lilly under strict manufacturing rules, use the exact base molecule, and typically list above $1,000 to $1,350 per month without insurance. Compounded versions from licensed 503A pharmacies have been available at $150 to $400 per month, but access rules tightened hard in 2025-2026. The safety catch: semaglutide sodium and semaglutide acetate are NOT the same molecule as the semaglutide in Wegovy or Ozempic. They are salt forms, and US regulators have explicitly warned they have not been shown to be safe or effective.

IfIf you're receiving compounded semaglutide or tirzepatide
Thenthen verify the pharmacy is state-licensed, uses the base molecule, and can provide a batch-specific CoA
IfIf the pharmacy can't confirm it's using semaglutide base (not sodium, not acetate)
Thenthen don't use the product
IfIf cost alone is your reason for compounded
Thenthen know that cost alone does not satisfy the 503A exception, and your prescriber must document a clinical reason
Key facts
  • Brand options (from prescribing labels): Wegovy (semaglutide) for chronic weight management; Ozempic (semaglutide) for type 2 diabetes; Mounjaro (tirzepatide) for type 2 diabetes; Zepbound (tirzepatide) for chronic weight management and obstructive sleep apnea. Your provider sets the strength and titration.
  • Typical brand list price: about $1,000 to $1,350 per month without insurance
  • 503A pharmacy: narrow individual-patient exception remains (documented allergy or medical necessity, cost savings alone does not qualify)
  • 503B outsourcing: fully prohibited from compounding tirzepatide as of March 19, 2025
  • Typical compounded cost: $150 to $400 per month when accessible
  • Salt form warning: semaglutide sodium / acetate and tirzepatide sodium / acetate are NOT equivalent to the base form; US regulators have issued explicit warnings
  • FAERS pharmacovigilance analysis: higher odds of preparation errors, contamination, and hospitalization for compounded vs non-compounded GLP-1s
Get more like this

Your guided peptide companion.

PRTCL walks beginners through their first peptide with confidence - guided reconstitution, syringe unit math from your own numbers, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.

  • · Guided walkthrough for your first dose
  • · Your vial and your dose, converted into syringe units
  • · Vial inventory and dose log tracking
  • · A library where every claim cites its source

Free to start.

PRTCL is educational. Always talk to a licensed provider about your situation.